March 30, 2017

Verseon Corporation (“Verseon” or the “Company”)

Unique mechanism of action of Verseon’s novel class of anticoagulants to be presented at American Chemical Society meeting

Novel pharmacology may lead to safer anticoagulants

FREMONT, Calif.—Verseon scientists will present research on the Company’s novel class of oral anticoagulants at the 253rd American Chemical Society National Meeting in San Francisco on April 2, 2017. The two posters will cover experiments showing that Verseon’s direct thrombin inhibitors act through reversible covalent inhibition and how this leads to novel pharmacology. In preclinical testing, these inhibitors exhibit strong efficacy without disruption of platelet function, resulting in substantially reduced bleeding.

Verseon’s anticoagulants potently inhibit fibrinogen cleavage, thrombin generation, and the activation of other endogenous substrates of thrombin. However, due to their novel mechanism of action, they are substantially weaker inhibitors of thrombin-mediated platelet activation than the NOACs and therefore do not disrupt platelet function. As a consequence, the Verseon inhibitors show significantly reduced bleeding in preclinical testing, while in vivo models of thrombosis indicate that they prevent clot formation with efficacy comparable to current anticoagulants.

“Our class of direct thrombin inhibitors act through a distinctive mechanism that results in their remarkable pharmacology and reduced bleeding,” said Dr. Kevin Short, Director, Discovery Planning.

Details of the posters, to be revealed at the American Chemical Society conference, are as follows:

Poster title: Direct thrombin inhibitors with a novel, reversible, covalent mechanism of action
Poster number: MEDI 194
Session name: Division of Medicinal Chemistry, General Posters
Date and time: Sunday, April 2, 2017; eve

Poster title: Novel, highly selective direct thrombin inhibitors: In vivo studies demonstrate efficacy with lower bleeding risk
Poster number: MEDI 272
Session name: Division of Medicinal Chemistry, General Posters
Date and time: Sunday, April 2, 2017; eve

About Verseon’s anticoagulation program

Verseon’s potent, highly selective, oral direct thrombin inhibitors act through reversible covalent inhibition, a unique mode of action. Preclinical studies show that Verseon’s inhibitors act as effective anticoagulants in multiple efficacy studies, but do not disrupt platelet function. This unique feature could explain their observed low bleeding risk. One of Verseon’s lead candidates furthermore shows very low renal clearance, a highly desirable property for patients with impaired renal function.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

-Ends-

For further information please contact

Verseon Corporation www.verseon.com
Arthur Shmurun / Amy Thai +1 (510) 225 9000
Cenkos Securities (NOMAD and Joint Broker)
Neil McDonald / Beth McKiernan +44 (0) 20 7397 8900
Cantor Fitzgerald Europe (Joint Broker)
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000
Mirabaud Securities LLP (Joint Broker)
Peter Krens +44 (0) 20 7321 2508

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE GENERALLY STATEMENTS THAT ARE NOT HISTORICAL FACTS. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE WORDS "EXPECTS," "ANTICIPATES," "BELIEVES," "INTENDS," "ESTIMATES," "PLANS," "WILL," “OUTLOOK” AND SIMILAR EXPRESSIONS. FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT PLANS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS, AND SPEAK ONLY AS OF THE DATE THEY ARE MADE. WE UNDERTAKE NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT IN LIGHT OF NEW INFORMATION OR FUTURE EVENTS, EXCEPT AS OTHERWISE REQUIRED BY LAW. FORWARD-LOOKING STATEMENTS INVOLVE INHERENT RISKS AND UNCERTAINTIES, MOST OF WHICH ARE DIFFICULT TO PREDICT AND ARE GENERALLY BEYOND OUR CONTROL. ACTUAL RESULTS OR OUTCOMES MAY DIFFER MATERIALLY FROM THOSE IMPLIED BY THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE IMPACT OF A NUMBER OF FACTORS.

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Three different therapeutic areas, all with unmet (or poorly met) medical needs